Benzodiazepines (BZDs) are commonly prescribed to older adults with depression, but it is unknown whether they improve antidepressant (AD) adherence or depressive symptoms. We followed 297 older veterans diagnosed with depression and provided a new AD medication prospectively for 4 months. Data include validated self-report measures and VA pharmacy records. At initial assessment, 20.5% of participants were prescribed a BZD. Those with a BZD prescription at baseline were significantly more likely than those without to have a personality disorder, schizophrenia spectrum disorder, or other anxiety disorder, and higher depressive symptom and anxiety symptom scale scores on average. In adjusted regressions, BZD use was not significantly associated with AD adherence, any improvement in depressive symptoms, or a 50% reduction in depressive symptoms. Our results suggest BZD use concurrent with AD treatment does not significantly improve depressive outcomes in older veterans.
CooperCBebbingtonPMcManusS. The treatment of common mental disorders across age groups: results from the 2007 Adult Psychiatric Morbidity Survey. J Affect Disord. 2010;127(1-3):96–101.
2.
JormAFGraysonDCreaseyHWaiteLBroeGA. Long-term benzodiazepine use by elderly people living in the community. Aust NZ J Publ Health. 2000;24(1):7–10.
3.
LeeDMartiniNMoyesSHaymanKZolezziMKerseN. Potentially inappropriate medication use: the Beers’ Criteria used among older adults with depressive symptoms. J Prim Health Care. 2013;5(3):182–190.
4.
AparasuRRMortJRBrandtH. Psychotropic prescription use by community-dwelling elderly in the United States. J Am Geriatr Soc. 2003;51(5):671–677.
5.
GraySLEggenAEBloughDBuchnerDLaCroixAZ. Benzodiazepine use in older adults enrolled in a health maintenance organization. Am J Geriatr Psychiatry. 2003;11(5):568–576.
6.
MamdaniMRapoportMShulmanKIHerrmannNRochonPA. Mental health-related drug utilization among older adults: prevalence, trends, and costs. Am J Geriatr Psychiatry. 2005;13(10):892–900.
7.
VoyerPPrévilleMCohenDBerbicheDBélandSG. The prevalence of benzodiazepine dependence among community-dwelling older adult users in Quebec according to typical and atypical criteria. Can J Aging. 2010;29(2):205–213.
8.
DavidsonJR. Major depressive disorder treatment guidelines in America and Europe. J Clin Psychiat. 2010;71 (suppl e1):e04.
9.
EganMMorideYWolfsonCMonetteJ. Long-term continuous use of benzodiazepines by older adults in Quebec: prevalence, incidence and risk factors. J Am Geriatr Soc. 2000;48(7):811–816.
10.
McMillanJMMDAitkenEBMHolroyd-LeducJMMD. Management of insomnia and long-term use of sedative-hypnotic drugs in older patients. Can Med Assoc J. 2013;185(17):1499–1505.
11.
SimonGELudmanEJ. Outcome of new benzodiazepine prescriptions to older adults in primary care. Gen Hosp Psychiatry. 2006;28(5):374–378.
12.
CookJMarshallRMasciCCoyneJ. Physicians’ perspectives on prescribing benzodiazepines for older adults: a qualitative study. J Gen Intern Med. 2007;22(3):303–307.
13.
Assem-HilgerEJungwirthSWeissgramSKirchmeyrWFischerPBarnasC. Benzodiazepine use in the elderly: an indicator for inappropriately treated geriatric depression?Int J Geriatr Psychiatry. 2009;24(6):563–569.
14.
PfeifferPNGanoczyDZivinKValensteinM. Benzodiazepines and adequacy of initial antidepressant treatment for depression. J Clin Psychopharmacol. 2011;31(3):360.
15.
FurukawaTStreinerDYoungLKinoshitaY. Antidepressants plus benzodiazepines for major depression. Cochrane Database Syst Rev. 2001;2: CD001026.
16.
FurukawaTStreinerDYoungL. Antidepressant and benzodiazepine for major depression. Cochrane Database Syst Rev. 2002;(1):CD001026.
17.
KalesHCNeaseDEJrSireyJA. Racial differences in adherence to antidepressant treatment in later life. Am J Geriatr Psychiatry. 2013;21(10):999–1009.
18.
CallahanCMUnverzagtFWHuiSLPerkinsAJHendrieHC. Six-item screener to identify cognitive impairment among potential subjects for clinical research. Med Care. 2002;40(9):771–781.
19.
KroenkeKSpitzerR. The PHQ -9: a new depression diagnostic and severity measure. Psychiatr Ann. 2002;32(9):1–7.
20.
SireyJABruceMLAlexopoulosGSPerlickDAFriedmanSJMeyersBS. Stigma as a barrier to recovery: perceived stigma and patient-rated severity of illness as predictors of antidepressant drug adherence. Psychiatr Serv. 2001;52(12):1615–1620.
21.
SireyJABruceMLAlexopoulosGS. Perceived stigma as a predictor of treatment discontinuation in young and older outpatients with depression. Am J Psychiatry. 2001;158(3):479–481.
22.
ValensteinMKimHMGanoczyD. Higher-risk periods for suicide among VA patients receiving depression treatment: prioritizing suicide prevention efforts. J Affect Disord. 2009;112(1-3):50–58.
23.
KroenkeKSpitzerRLWilliamsJBWLöweB. The patient health questionnaire somatic, anxiety, and depressive symptom scales: a systematic review. Gen Hosp Psychiatry. 2010;32(4):345–359.
24.
McMillanDGilbodySRichardsD. Defining successful treatment outcome in depression using the PHQ-9: a comparison of methods. J Affect Disord. 2010;127(1-3):122–129.
25.
The Management of MDD Working Group. VA/DoD Clinical Practice Guideline: Management of Major Depressive Disorder (MDD). Washington D.C., WA: Department of Veterans Affairs, Department of Defense; 2009.
26.
SvarstadBLChewningBASleathBLClaessonC. The Brief Medication Questionnaire: a tool for screening patient adherence and barriers to adherence. Patient Educ Couns. 1999;37(2):113–124.
27.
RicklesNMSvarstadBL. Relationships between multiple self-reported nonadherence measures and pharmacy records. Res Social Adm Pharm. 2007;3(4):363–377.
28.
ValensteinMCopelandLABlowFC. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care. 2002;40(8):630–639.
29.
WareJJrKosinskiMKellerSD. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Medical Care. 1996;34(3):220–233.
30.
LawtonMPMossMFulcomerMKlebanMH. A research and service oriented multilevel assessment instrument. J Gerontol B Psychol Sci Soc Sci. 1982;37(1):91–99.
31.
DeaconBJAbramowitzJSWoodsCMTolinDF. The Anxiety Sensitivity Index-Revised: psychometric properties and factor structure in two nonclinical samples. Behav Res Ther. 2003;41(12):1427–1449.
32.
ZigmondASSnaithRP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361–370.
33.
CharlsonMEPompeiPAlesKLMacKenzieCR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
34.
WechslerD. WMS-III: Wechsler Memory Scale Administration and Scoring Manual. Psychological Corporation; San Antonio, TX, 1997.
35.
GrahamJW. Missing data analysis: making it work in the real world. Annu Rev Psychol. 2009;60:549–576.
36.
SchaferJLGrahamJW. Missing data: our view of the state of the art. Psychol Methods. 2002;7(2):147–177.
37.
Parraga MartinezILopez-Torres HidalgoJDel Campo Del CampoJMVillena FerrerAMorena RayoSEscobar RabadanF. Adherence to patients antidepressant treatment and the factors associated of non-compliance. Aten Primaria. 2014;46(7):357–366.
38.
BurraTAChenEMcIntyreRSGraceSLBlackmoreERStewartDE. Predictors of self-reported antidepressant adherence. Behav Med. 2007;32(4):127–134.
39.
FortneyJCPyneJMEdlundMJ. Reasons for antidepressant nonadherence among veterans treated in primary care clinics. J Clin Psychiatry. 2011;72(6):827–834.
40.
LeeMSLeeHYKangSG. Variables influencing antidepressant medication adherence for treating outpatients with depressive disorders. J Affect Disord. 2010;123(1-3):216–221.
41.
LandiFOnderGCesariM. Psychotropic medications and risk for falls among community-dwelling frail older people: an observational study. J Gerontol A Biol Sci Med Sci. 2005;60(5):622–626.
42.
TamblynRAbrahamowiczMBergerRdMcLeodPBartlettG. A 5-year prospective assessment of the risk associated with individual benzodiazepines and doses in new elderly users. J Am Geriatr Soc. 2005;53(2):233–241.
43.
WangPSBohnRGlynnRJMogunHAvornJ. Hazardous benzodiazepine regimens in the elderly: effects of half-life, dosage, and duration on risk of hip fracture. Am J Psychiatry. 2001;158(6):892–898.
44.
GraySLPenninxBWJHBloughDK. Benzodiazepine use and physical performance in community-dwelling older women. J Am Geriatr Soc. 2003;51(11):1563–1570.
45.
VerdouxHLagnaouiRBegaudB. Is benzodiazepine use a risk factor for cognitive decline and dementia? A literature review of epidemiological studies. Psychol Med. 2005;35(3):307–315.
46.
HoganDBMaxwellCJFungTSEblyEM. Prevalence and potential consequences of benzodiazepine use in senior citizens: results from the Canadian Study of Health and Aging. Can J Clin Pharmacol. 2003;10(2):72–77.
47.
WeichSPearceHLCroftP. Effect of anxiolytic and hypnotic drug prescriptions on mortality hazards: retrospective cohort study. BMJ. 2014;348:g1996.
48.
ShiLLiuJKolevaYFonsecaVKalsekarAPawaskarM. Concordance of adherence measurement using self-reported adherence questionnaires and medication monitoring devices. Pharmacoeconomics. 2010;28(12):1097–1107.
